Introduction
Early stages of tumorigenesis frequently involve the suppression of default apoptotic signals that represent the first line of defense against cancer (Hanahan and Weinberg, 2000) . Signals that suppress apoptotic programs have been referred to as survival signals (Foster, 2004; Guertin and Sabatini, 2005) . Phosphatidylinositol-3-kinase (Luo et al., 2003) and phospholipase D (PLD) (Foster, 2006) , both of which generate survival signals in a variety of human cancers, target mTOR, the mammalian target of rapamycin. mTOR is a protein kinase that is sensitive to environmental stresses that restrict cell growth and proliferation (Sawyers, 2003; Guertin and Sabatini, 2005) . Targeting mTOR in anti-cancer therapeutic strategies represents a promising approach to attack cancer cells by downregulating protective apoptotic programs (Sawyers, 2003; Foster, 2004; Guertin and Sabatini, 2005) . Although there have been some successes, clinical trials with rapamycin and rapamycin derivatives such as CCI-779 and RAD-001 have been largely disappointing (Sawyers, 2003; Guertin and Sabatini, 2005) . One of the problems with the use of rapamycin as an anti-cancer drug is that in most cases, rapamycin is cytostatic rather than cytotoxic and induces G 1 cell cycle arrest, rather than apoptosis (Neshat et al., 2001; Podsypanina et al., 2001; Law et al., 2002) .
MDA-MB-231 human breast cancer cells have a survival signal generated by PLD that is dependent on mTOR (Hanahan and Weinberg, 2000; Zhong et al., 2003; Chen et al., 2005; Foster, 2007) . Rapamycin treatment of MDA-MB-231 cells resulted in apoptosis in the absence of serum, but not in the presence of serum (Chen et al., 2005) . These data indicated that a factor(s) in serum was suppressing rapamycin-induced apoptosis. Since previous reports indicated that rapamycin induces a G 1 cell cycle arrest, we investigated the effect of serum growth factors on cell cycle progression and the ability to suppress rapamycin-induced apoptosis. Transforming growth factor-b (TGF-b) is a factor present in serum that has been implicated in the suppression of cell cycle progression in MDA-MB-231 cells (Chen et al., 2001; Siegel and Massague, 2003) . We therefore investigated whether TGF-b in serum is responsible for the cell cycle arrest induced by rapamycin in MDA-MB-231 cells in the presence of serum and whether TGF-b could suppress the apoptosis induced by rapamycin in the absence of serum.
Results

TGF-b suppresses rapamycin-induced apoptosis in MDA-MB-231 cells
We first examined the effect of rapamycin on cell cycle progression using flow cytometric analysis of DNA content in the presence and absence of serum. As shown in Figure 1a , rapamycin treatment of MDA-MB-231 cells in the presence of serum resulted in an increase in the percentage of cells with a G 1 DNA content and a reduction of cells with greater than G 1 DNA content. These data are consistent with those reported by Law et al. (2002) , where they also observed that rapamycin causes cells to accumulate in G 1 . Their data revealed a more significant accumulation in G 1 , which was likely due to a 24-h treatment rather than the 18-h treatment used here. We used the 18-h time point because cells undergoing apoptosis are harvested better at 18 than 24 h. If we treat with rapamycin for 24 h, we too observe a better accumulation in G 1 (data not shown). In the absence of serum, rapamycin treatment resulted in virtually all of the cells containing subgenomic levels of DNA-consistent with the previously reported rapamycin-induced apoptosis observed in these cells when deprived of serum (Chen et al., 2005) . Thus, while rapamycin induces apoptosis in the absence of serum, in the presence of serum, rapamycin blocks cell cycle progression in G 1 .
The data in Figure 1a indicate that a component(s) in serum causes a block in cell cycle progression when cells are treated with rapamycin. Serum is a complex mixture of growth factors; however, if the effect is due to suppression of cell cycle progression, then a serum factor capable of suppressing cell cycle progression could be implicated. We therefore examined the effect of TGF-b, which can suppress cell cycle progression (Law et al., 2002; Siegel and Massague, 2003) on the ability of rapamycin to induce apoptosis in serum-starved MDA-MB-231 cells. As demonstrated previously (Chen et al., 2005) and indicated in Figure 1a , there is a large loss in cell viability in MDA-MB-231 cells subjected to serum withdrawal in the presence of rapamycin (Figure 1b) . The loss in cell viability was accompanied by an increase in the cleavage of the caspase-3 substrate poly-ADPribose polymerase (PARP; Figure 1b) , indicating that the cell death was due to apoptosis. If TGF-b was added along with rapamycin, the effect of rapamycin on cell viability and PARP cleavage was reversed-almost as effectively as observed for serum (Figure 1b ). The addition of IGF1, a growth factor that facilitates cell cycle progression (Baserga et al., 2003) , did not reverse the effect of rapamycin (Figure 1b) . We also examined the effect of TGF-b on DNA content per cell in rapamycin-treated MDA-MB-231 cells. As shown in Figure 1c , TGF-b eliminated most of the sub-genomic DNA caused by rapamycin treatment and led to a 5 cells/60 mm plate. Twenty-four hours later, the cells were provided with either fresh media containing 10% serum, fresh media containing 10% serum and 20 mM rapamycin (Rap), fresh media containing 0% serum or fresh media containing 0% serum and 20 mM rapamycin as indicated. The cells were then subjected to flow cytometric analysis 18 h later as described in Materials and methods. The DNA content per cell shown graphically above is from a representative experiment that was repeated three times. The percentage of cells in G 1 was: serum, 56%; serum þ Rap, 67%; serum free, 60%; and serum free þ Rap, o1%. (b) MDA-MB-231 cells were plated as above and then shifted to media containing 10% serum (Ser), 20 mM rapamycin, 10 ng/ml TGF-b and 10 ng/ml IGF-1 as indicated. Eighteen hours later, cell viability (upper graph) and PARP cleavage (lower blot, Cl PARP) were determined as described in Materials and methods. The western blot for PARP was examined for loading by reprobing with an antibody raised against actin. (c) MDA-MB-231 cells in serum-free media in the presence of rapamycin (20 mM) with or without TGF-b (10 ng/ml) were subjected to flow cytometric analysis as in (a). (d) MDA-MB-231 cells were plated as above and put in serum-free media 24 h later. TGF-b (10 ng/ml) and rapamycin (Rap) (20 mM) was added as indicated and the levels of p21 and phosphorylated Rb (P-Rb) were determined 18 h later by western blot analysis. Blots were reprobed with an antibody to actin and Rb to control for loading. Error bars for the graph in (b) represent the s.d. from three independent experiments. The western blots in (b and d) and the flow cytometry in (a and c) are representative of at least three independent experiments. PARP, poly-ADP-ribose polymerase; TGF-b, transforming growth factor-b.
profile that indicated a predominant G 1 DNA content for surviving cells. These data demonstrate that TGF-b, like serum, suppresses rapamycin-induced apoptosis.
Because of the enrichment of cells with G 1 DNA content upon rapamycin treatment, we analyzed the effect of TGF-b and rapamycin on regulators of the G 1 / S cell cycle progression. To this end, we examined the effect of TGF-b and rapamycin on the level of the cyclin-dependent kinase inhibitor p21 and the phosphorylation of the tumor suppressor Rb, which is phosphorylated by cyclin-dependent kinases. MDA-MB-231 cells were put in serum-free media for 18 h in the presence of rapamycin and/or TGF-b and the levels of p21 and Rb phosphorylation were determined by western blot analysis. As shown in Figure 1f , rapamycin and TGF-b synergistically stimulated increases in the level of p21 and decreases in the phosphorylation state of Rb. Since phosphorylation of Rb is critical for progression through G 1 (Ho and Dowdy, 2002) , these data are consistent with the hypothesis that in the presence of rapamycin, TGF-b signaling is derepressed and induces G 1 arrest-in part by increasing p21 expression and suppressing Rb phosphorylation.
TGF-b signaling is required for the suppression of rapamycin-induced apoptosis by serum While the data in Figure 1 demonstrate that TGF-b is able to suppress the apoptosis induced by rapamycin in MDA-MB-231 cells, it does not indicate whether TGF-b in serum is responsible for suppressing rapamycininduced apoptosis. We therefore pretreated the serum with a neutralizing anti-TGF-b antibody previously demonstrated to block the effects of TGF-b (Ho and Dowdy, 2002) . As shown in Figure 2a , rapamycin induced both cell death and PARP cleavage in the presence of the neutralizing anti-TGF-b antibody. To establish further that the anti-TGF-b antibody used was blocking TGF-b signaling, we examined the effect of this antibody on Smad2 phosphorylation, which occurs in response to TGF-b (Siegel and Massague, 2003) . As shown in Figure 2b , the anti-TGF-b antibody also suppressed Smad2 phosphorylation induced by serum. These data indicate that TGF-b in serum was at least partially responsible for the ability of serum to suppress the apoptosis induced by rapamycin in MDA-MB-231 cells. We also examined the effect of an inhibitor of the TGF-b receptor SB-431542 (Inman et al., 2002) on the ability of rapamycin to induce apoptosis in MDA-MB-231 cells. As shown in Figure 2c , SB-431542 had the same effect as the neutralizing TGF-b antibody and made rapamycin an apoptotic drug on the MDA-MB-231 cells. SB-431542 has no effect on cell viability in the absence of rapamycin. These data indicate that the TGF-b present in serum is sufficient to suppress the apoptotic effect of rapamycin.
Protein kinase Cd (PKCd) has been implicated in signals generated by TGF-b (Perillan et al., 2002; Runyan et al., 2003) . Therefore, to establish further that derepression of TGF-b signaling was critical for the G 1 arrest induced by rapamycin, we examined whether suppression of PKCd, like suppression of TGF-b directly, prevented G 1 arrest by rapamycin and led to apoptosis. We first examined the effect of rottlerin, a compound that has been shown to suppress PKCd activity in vivo (Lu et al., 1997) on rapamycin-treated MDA-MB-231 cells. As shown in Figure 2d , in the presence of rottlerin, rapamycin induced apoptosis and PARP cleavage in MDA-MB-231 cells in the presence of serum. To confirm this result, we examined the effect of suppressing PKCd expression with PKCd small interfering RNA (siRNA). MDA-MB-231 cells were transfected with either a nonspecific control or PKCd-specific siRNA and the effect of TGF-b and rapamycin on cell viability and PARP cleavage was evaluated. As shown in Figure 2e , the PKCd siRNA reversed the protective effect of TGF-b on rapamycin-induced apoptosis. We also examined the effect of PKCd siRNA on PKCd levels and on the induction of p21 by TGF-b. As shown in Figure 2f , PKCd siRNA reduced PKCd expression and suppressed the expression of p21. We also examined the effect of suppressing PKCd activity on Smad2 phosphorylation, and as shown in Figure 2g , rottlerin treatment reduced the Smad2 phosphorylation induced by both serum and TGF-b. These data indicate that the effects of TGF-b on cell cycle progression and rapamycin-induced apoptosis are dependent upon PKCd. Collectively, the data in Figure 2 suggest that the TGF-b present in serum is required for the G 1 arrest induced by rapamycin in the presence of serum, and that suppression of TGF-b signaling results in apoptosis instead of G 1 arrest in the presence rapamycin.
Blocking cells in S phase restores the ability of rapamycin to induce apoptosis in the presence of serum The data provided in Figure 1 suggest that serum and TGF-b suppress rapamycin-induced apoptosis by blocking passage through the G 1 /S cell cycle checkpoint. We therefore pretreated MDA-MB-231 cells with aphidicolin, which blocks cell cycle progression after the G 1 /S cell cycle checkpoint in early S phase (Borel et al., 2002) . As shown in Figure 3a , aphidicolin treatment leads to an accumulation of cells with a G 1 DNA contentindicating that the aphidicolin was inducing cell cycle arrest at the G 1 /S transition as reported. As shown in Figure 3b , pretreating cells with aphidicolin restored the ability of rapamycin to induce apoptosis in the presence of serum. These data indicate that cells that pass the G 1 / S cell cycle checkpoint and enter S phase become sensitive to the apoptotic effects of rapamycin.
Human cancer cells with defective TGF-b or PKCd signaling are killed by rapamycin in the presence of either serum or TGF-b Defective TGF-b signaling has been reported in SW480 colon and MDA-MB-468 breast cancer cells by virtue of mutations in the Smad4 gene (Runyan et al., 2003; Jackson et al., 2005) . BT-549 breast cancer cells do not express PKCd (Jackson et al., 2005) , which is required for TGF-b signals (Perillan et al., 2002; Runyan et al., 2003) . We therefore examined the effect of rapamycin TGF-b suppresses rapamycin-induced apoptosis N Gadir et al Figure 1b and then shifted to media containing 10% serum, 20 mM rapamycin (Rap), and anti-TGF-b1 antibody (2 mg/ml) as indicated. Eighteen hours later, cell viability and PARP cleavage were determined as in Figure 1b. (b) MDA-MB-231 cells were plated as above and put in media containing either 0 or 10% serum, or 0% serum and TGF-b (10 ng/ml). The anti-TGF-b1 antibody (2 mg/ml) was added as indicated. Eighteen hours later, the levels of phosphorylated Smad2 (P-Smad2) and total Smad2 were determined by western blot. (c) MDA-MB-231 cells were plated as above and then shifted to media containing 10% serum, 20 mM rapamycin (Rap), and SB-431542 (10 mM) as indicated. Eighteen hours later, cell viability and PARP cleavage were determined as in (a). (d) MDA-MB-231 cells were plated as in Figure 1 and then shifted to media containing 10% serum, 20 mM rapamycin (Rap), and 3 mM rottlerin (Rott) as indicated. Eighteen hours later, cell viability and PARP cleavage were determined as in Figure 1 . (e) MDA-MB-231 cells were plated as in Figure 1 and put in media containing 10% serum for 24 h. Cells were then transfected with either control or PKCd siRNA as described in Materials and methods. Forty-eight hours later, the cells were put in serum-free media containing TGF-b (10 ng/ml) and rapamycin (20 mM) as indicated. Cell viability and PARP cleavage were determined 18 h later as in Figure 1 . (f) MDA-MB-231 cells were plated as in Figure 1 and put in media containing 10% serum for 24 h. Cells were then transfected with either control or PKCd siRNA as in (d). Forty-eight hours later, the cells were put in serum-free media containing TGF-b (10 ng/ml). The levels of PKCd, p21, and actin were then determined by western blot analysis 24 h later as in Figure 1 . (g) MDA-MB-231 cells were plated as above and put in media containing either 0 or 10% serum, or TGF-b (10 ng/ml) as indicated. Rottlerin (3 mM) was added as indicated. Eighteen hours later, the levels of phosphorylated Smad2 (P-Smad2) and total Smad2 were determined by western blot. Error bars for the graphs in (a, c-e) represent the s.d. from at least two independent experiments. Western blots are representative of at least two independent experiments. PARP, poly-ADP-ribose polymerase; TGF-b, transforming growth factor-b.
TGF-b suppresses rapamycin-induced apoptosis
N Gadir et al on these cells in the presence and absence of serum. As shown in Figure 4a , rapamycin induced apoptosis in the SW480, MDA-MB-468 and BT549 cells in the presence of serum as indicated by increased cell death and PARP cleavage. Significantly, TGF-b was unable to suppress the apoptosis observed in the absence of serum (Figure 4a ). The ability of rapamycin to kill the SW480 and MDA-MB-468 cells was somewhat less than that observed for the BT549 cells. This may reflect the ability of TGF-b to partially suppress growth in Smad4-deficient cells (Fink et al., 2001 (Fink et al., , 2004 . These data indicate that cells defective in TGF-b signaling are uniquely sensitive to the effects of rapamycin in that rapamycin induces apoptosis rather than cell cycle arrest in the presence of serum or TGF-b. We also wanted to determine whether the phenomenon of combining strategies that target mTOR with strategies to suppress TGF-b signaling could be observed in cells other than the MDA-MB-231 cells. To this end, we examined the effect of rapamycin on MCF-7 human breast cancer cells that have intact TGF-b signals (Kalkhoven et al., 1995) in combination with the anti-TGF-b antibody and the TGF-b receptor inhibitor SB-431542. The MCF-7 cells were placed in culture in the presence of serum. As shown in Figure 4b , rapamycin induced substantially more cell death in the presence of serum than was observed in the MDA-MB-231 cells. However, treatment with either anti-TGF-b antibody or SB-413524 significantly increased cell death and PARP cleavage in the presence of serum and rapamycin (Figure 4b ). These data further support the concept that the absence of TGF-b signaling increases sensitivity to rapamycin.
Discussion
Rapamycin has great potential as an anti-cancer drug in that it targets mTOR, a critical mediator of survival signals in cancer cells that suppresses protective apoptotic programs (Sawyers, 2003; Foster, 2004; Guertin and Sabatini, 2005) . A potential complication in the use of rapamycin in anti-cancer therapies is that in many cases, the effect of rapamycin is cytostatic and does not kill cancer cells (Neshat et al., 2001; Podsypanina et al., 2001; Law et al., 2002) . We reported previously that under conditions of serum withdrawal, rapamycin induces apoptosis in MDA-MB-231 breast cancer cells (Chen et al., 2005) . Consistent with the previous studies, we find that in the presence of serum growth factors, rapamycin induces G 1 arrest, rather than apoptosis. We demonstrated here that the ability of rapamycin to induce G 1 arrest in the presence of serum is dependent upon TGF-b, and that TGF-b is sufficient to suppress rapamycin-induced apoptosis in MDA-MB-231 cells deprived of serum. Importantly, suppression of TGF-b or PKCd signaling restored the ability of rapamycin to induce apoptosis rather than G 1 arrest in the presence of serum. Moreover, human cancer cell lines with defects in TGF-b or PKCd signaling were killed by rapamycin in the presence of serum. The finding that PKCd is required for TGF-b to suppress cell cycle progression in G 1 is intriguing in that, like TGF-b, PKCd has been implicated in both tumor suppression and promotion (Jackson and Foster, 2004) . These data indicate that rapamycin or other agents that target mTOR could be made a more effective anti-cancer option in combination with the suppression of TGF-b signals that cause G 1 arrest. The data also point out that tumors with defective TGF-b signaling may be selectively killed by rapamycin.
It is not clear how rapamycin induces G 1 arrest in the presence of TGF-b. However, since TGF-b is present in serum, it is likely that suppression of mTOR by rapamycin derepresses TGF-b signals in MDA-MB-231 cells. Massague's group reported previously that MDA-MB-231 cells are not responsive to the antiproliferative effects of TGF-b (Chen et al., 2001) . The data reported here indicate that the suppressed TGF-b signaling in these cells is due to mTOR. Consistent with this interpretation, it was recently reported that mTOR suppresses TGF-b signaling by inhibiting Smad3 phosphorylation (Song et al., 2006) . Importantly, Moses and colleagues have shown that TGF-b and rapamycin work Figure 1a and put in fresh media containing 10% serum 24 h later. The cells were treated with 5 mg/ml aphidicolin (Aph) for 18 h at which point the cells were subjected to fluorescent-activated cell sorting (FACS) analysis as in Figure 1a to investigate the effect of aphidicolin on cell cycle progression. The percentage of cells in G 1 was: serum, 49%; serum þ aphidicolin, 59%. (b) Rapamycin (Rap; 20 mM) was then added and cell viability and PARP cleavage was determined 18 h later as in Figure 1b . The experiment shown is representative of two independent experiments. PARP, poly-ADP-ribose polymerase; TGF-b, transforming growth factor-b.
TGF-b suppresses rapamycin-induced apoptosis N Gadir et al synergistically to induce G 1 arrest in MDA-MB-231 cells (Law et al., 2002) . Their data and ours indicate that whereas TGF-b by itself was unable to induce cell cycle arrest in MDA-MB-231 cells, rapamycin and TGF-b together did induce G 1 cell cycle arrest (Law et al., 2002) . Similarly, rapamycin enhanced TGF-b-induced growth arrest in prostate cancer cells (van der Poel et al., 2003 (van der Poel et al., , 2004 . These studies indicate that rapamycin enhances intracellular signals generated by TGF-b leading to cell cycle arrest. Current evidence is consistent with the hypothesis that survival signals mediated by mTOR involve both suppression of signals generated by TGF-b that result in G 1 cell cycle arrest, and the suppression of apoptotic programs that prevent cells in S phase from progressing to mitosis. A model for the differential effects of rapamycin-in the presence and absence of TGF-b signaling-is shown schematically in Figure 5 . It is proposed that if TGF-b signaling is suppressed, rapamycin stimulates progression through G 1 into S phase, where the lack of mTOR activity signals the cells to undergo apoptosis. A rationale for apoptosis in the absence of mTOR activity is that mTOR has been widely implicated as a sensor of nutritional sufficiency (Schmelzle and Hall, 2000) . Thus, in the absence of mTOR, cells sense that there is not sufficient nutrition to complete the cell cycle.
There are many tumors with genetic defects in TGF-b signaling, particularly in the Smad4 gene (Miyaki and Kuroki, 2003) , which localizes to a region of chromosome 18q, where there is considerable loss-of-heterozygosity especially in colon (Popat and Houlston, 2005) and pancreatic (Jaffe et al., 2002) cancers. Thus, there may be a large number of tumors with defects in the TGF-bsignaling pathway that could be effectively targeted with rapamycin or rapamycin derivatives. Another important . p21 and p27, by inhibiting cyclin D and E along with there partner cyclin-dependent kinases (CDK) 4/6 and 2 respectively, suppress the phosphorylation of Rb to P-Rb, leading to G1 arrest rather than progression into S phase. mTOR promotes progression through S phase and suppresses apoptosis. Thus, in the absence of mTOR signaling (in the presence of rapamycin), then cells undergo apoptosis as a default pathway activated when cells are unable to complete progression through S phase. TGF-b, transforming growth factor-b.
TGF-b suppresses rapamycin-induced apoptosis N Gadir et al consideration in the use of rapamycin is that it acts competitively with PLD-generated phosphatidic acid (Foster, 2004 (Foster, , 2006 (Foster, , 2007 necessitating higher levels of rapamycin in cells with elevated PLD activity (Chen et al., 2003 (Chen et al., , 2005 . Since many cancer cells, including all of the cell lines used in this study have elevated levels of PLD activity (our unpublished results), the dose of rapamycin used will also be important for effective use in clinical settings. Thus, the status of TGF-b signaling and PLD activity could be critical factors for determining whether rapamycin will be an effective and appropriate strategy for anti-cancer therapeutic strategies. The suppression of PLD activity could improve the efficacy of rapamycin as has been demonstrated in culture (Chen et al., 2003) . The use of rapamycin in therapeutic strategies for targeting cancers has been widely discussed because it is well tolerated, it is highly specific for mTOR, and because it targets survival signals in cancer cells (Sawyers, 2003; Foster, 2004) . The data reported here provide a rationale for using rapamycin in combination with strategies that suppress TGF-b and PKCd signaling, which makes rapamycin cytotoxic rather than cytostatic. The study also suggests that rapamycin treatment could be especially effective in treating the many cancers where TGF-b and PKCd signaling are already defective.
In conclusion, this study demonstrates that rapamycin induces apoptosis when cells cannot be arrested in G 1 by TGF-b signaling. The ability of TGF-b to suppress apoptosis is due to preventing cells from progressing through G 1 into S phase at which point, the lack of mTOR signaling causes the cells to decide to undergo apoptosis rather than replicate their DNA under these conditions. The implication from this study is that rapamycin could be used to specifically target human cancers with defects in TGF-b signaling, or alternatively rapamycin could be used effectively in combination with strategies for suppressing TGF-b signaling.
Materials and methods
Cells and cell culture conditions
The MDA-MB-231, SW480. 7, MCF-7, MDA-MB-468 and BT549 cells used in this study were obtained from the American Tissue Type Culture Collection and were maintained in Dulbecco's modified Eagles medium supplemented with 10% fetal bovine serum (HyClone, Logan, UT, USA). For transfection of siRNA, cells were plated at a density of 10 5 cells/60 mm plate 24 h before transfection. All transfections were performed using lipofectamine 2000 (Gibco, Carlsbad, CA, USA) according to the manufacturer's instructions.
Materials
Rapamycin and aphidicolin were obtained from Sigma, Atlanta (GA, USA). The PKCd inhibitor rottlerin was obtained from Calbiochem (San Diego, CA, USA) and the TGF-b inhibitor SB-431542 was from Sigma. TGF-b1 and the TGF-b1-blocking antibody (MAB2401) were from R&D Systems (Minneapolis, MN, USA). All other antibodies used in this work were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA) except the phospho-specific antibodies for Rb and Smad2, and the Smad2 and PARP antibodies, which were obtained from Cell Signaling (Danvers, MA, USA). PKCd and non-targeted-negative control siRNA duplexes were obtained from Qiagen (Valencia, CA, USA). The siRNA sequence for targeting PKCd was 5 0 -GAUGAAG GAGGCGCUCAGTT-3 0 .
Flow cytometric analysis
Cell suspensions were recovered and resuspended in the following fixing solution: 20 ml Â 1 phosphate-buffered solution (PBS), 2% bovine serum albumin (BSA), 0.1%. NaN 3 . Nine milliliters of 100% ethanol was added dropwise. Fixed cells were centrifuged, washed and then resuspended in a 500-ml sorting buffer: Â 1 PBS, 0.5% BSA, 1 mM ethylenediamine tetraacetic acid, 40 mg/ml propidium iodide, 100 mg/ml RNAse A, and filtered through 40-mm-diameter mesh to remove clumps of nuclei. Percentages of cells within each of the cell cycle compartments (G 0 -G 1 , S, or G 2 -M) were determined by flow cytometry (FACSCalibur; Becton Dickinson, Franklin Lakes, NJ, USA).
Cell viability and apoptosis
Cell viability was determined by Trypan blue exclusion as described previously (Chen et al., 2005) . Apoptosis was evaluated by examination of cleavage of the caspase-3 substrate PARP as described previously (Chen et al., 2005) . Apoptosis was also determined by examination of subgenomic DNA using flow cytometry as described above.
Western blot analysis
Proteins were extracted from cultured cells in modified RIPA buffer (Upstate, Charlottesville, VA, USA). Equal amounts of proteins were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis on polyacrylamide-separating gels. Electrophoresed proteins were then transferred to nitrocellulose and subjected to western blot analysis as described previously (Chen et al., 2003) .
